denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: an educational grant from Novartis Pharmaceuticals Corporation
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Anemias, sickle cell disease, Biological, Diseases, Therapies, Hemoglobinopathies
Hematology Disease Topics & Pathways:
Anemias, sickle cell disease, Biological, Diseases, Therapies, Hemoglobinopathies
Friday, December 4, 2020: 3:00 PM-6:00 PM
Chair:
Kenneth I. Ataga, MD, UTHSC Center for Sickle Cell Disease
Disclosures:
Ataga: Shire/Takeda: Research Funding; Global Blood Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novo Nordisk: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Research Funding; Modus Therapeutics: Honoraria; Bioverativ: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Research Funding; Forma Therapeutics: Consultancy; Editas Medicine: Honoraria.
Speakers:
Julie Kanter, MD, Comprehensive Sickle Cell Center, University of Alabama at Birmingham
,
Abdullah Kutlar, MD, Dr. William N. Agostas and Josephine R. Agostas Chair in Internal Medicine Medical College of Georgia
and
Bernard L. Lopez, MD, MS, CPE, FACEP, FAAEM, Sidney Kimmel Medical College, Thomas Jefferson University
Disclosures:
Kanter: Novartis: Consultancy; bluebird bio, inc: Consultancy, Honoraria; Sanofi: Consultancy; Medscape: Honoraria; Guidepoint Global: Honoraria; GLG: Honoraria; Jeffries: Honoraria; Cowen: Honoraria; Wells Fargo: Honoraria; NHLBI Sickle Cell Advisory Board: Membership on an entity's Board of Directors or advisory committees; SCDAA Medical and Research Advisory Board: Membership on an entity's Board of Directors or advisory committees; AGIOS: Membership on an entity's Board of Directors or advisory committees; BEAM: Membership on an entity's Board of Directors or advisory committees.
Significant acute and chronic pain as well as increased infection risk resulting from hemolytic anemia and vaso-occlusion crisis (VOC) underlying sickle cell disease (SCD) greatly impacts morbidity and mortality. As such, there has been a call to action to develop therapeutics to address these symptoms and their underlying causes. As such, there has been novel therapy made available for patients in late 2019, about which it is vital that clinicians receive timely and relevant education.
This activity is a virtual, interactive symposium that features a panel of expert faculty delivering clinically relevant, patient-centric information about the latest advances in sickle cell management. Focus will be placed on the implementation of practice strategies that align with current guidelines and emerging data. The activity will offer a state-of-the-art clinical update on management of SCD and related complications.
See more of: Satellite Symposia